A single-dose gene replacement therapy is found to improve movement ability in children over 2 years of age and teenagers with spinal muscular atrophy, according to research published in Nature ...

The Scottish Medical Consortium has approved the use of givinostat to treat children aged six and older who are still able to ...

Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy December ...

The Scottish Medical Consortium has approved the use of givinostat to treat children aged six and older who are still able to walk.

Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p ...

Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.

First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor ...

The 2-2-2 method focuses on effective volume. 'Muscle growth doesn't come from endless volume. It comes from effective volume ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

Plant-based proteins can provide a rich source of amino acids to support muscle recovery after exercise in cold weather.

This is a new position for Foresite Capital Management IV, LLC, representing 13.8% of reportable assets under management as ...

We came across a bullish thesis on Wave Life Sciences Ltd. on Valueinvestorsclub.com by zamperini. In this article, we will ...